Organizations experiencing contamination issues know that contamination may cause serious financial risks to their bottom line.

CONTAMINATING THE BOTTOM LINE
Every day contamination costs biotech, pharmaceutical, medical device, and high-tech companies money. If a product is contaminated, it can’t be sold. When this occurs, not only is the investment in raw materials and labor to make a microchip or heart valve lost, but the company has to start all over again and duplicate costs.

Pharmaceutical, biotech, and medical device companies with histories of contamination issues also risk delays in meeting Food and Drug Administration (FDA) regulations. Such delays can jeopardize competitive market advantages, put employees into costly, unproductive work holding patterns, and give a company’s reputation a black eye. When products aren’t getting out the factory door, companies bleed money.

Organizations experiencing contamination issues may also find it more difficult to retain the all-important certification of their systems by the International Organization for Standardization (ISO). Moreover, most customers won’t accept products from a company that isn’t ISO certified. Quite simply, contamination poses serious financial risks to a company’s bottom line.